Current Perspectives on Circulating Tumor DNA, Precision Medicine, and Personalized Clinical Management of Cancer

被引：71

作者：

Oliveira, Kelly C. S. ^{[1
]}

Ramos, Iago Barroso ^{[2
]}

Silva, Jessica M. C. ^{[1
]}

Barra, Williams Fernandes ^{[1
]}

Riggins, Gregory J. ^{[3
]}

Palande, Vikrant ^{[4
]}

Pinho, Catarina Torres ^{[1
]}

Frenkel-Morgenstern, Milana ^{[4
]}

Santos, Sidney E. B. ^{[1
]}

Assumpcao, Paulo P. ^{[1
]}

Burbano, Rommel R. ^{[5
]}

Calcagno, Danielle Queiroz ^{[1
]}

机构：

[1] Univ Fed Para, Nucleo Pesquisas Oncol, Belem, Para, Brazil

[2] Univ Fed Para, Programa Residencia Multiprofiss Saude, Hosp Univ Joao Barros Barreto, Belem, Para, Brazil

[3] Johns Hopkins Med, Brain Canc Biol & Therapy Res Lab, Baltimore, MD USA

[4] Bar Ilan Univ, Azrieli Fac Med, Safed, Israel

[5] Hosp Ophir Loyola, Lab Biol Mol, Belem, Para, Brazil

来源：

MOLECULAR CANCER RESEARCH | 2020年 / 18卷 / 04期

关键词：

CELL-FREE DNA; ACQUIRED-RESISTANCE; TREATMENT RESPONSE; SYSTEMIC THERAPY; LIQUID BIOPSIES; ESR1; MUTATIONS; PLASMA DNA; GENE; IDENTIFICATION; IMMUNOTHERAPY;

D O I：

10.1158/1541-7786.MCR-19-0768

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Circulating tumor DNA (ctDNA) has recently emerged as a minimally invasive "liquid biopsy" tool in precision medicine. ctDNA-genomic DNA fragments that are released into the bloodstream after the active secretion of microvesicles or tumor cell lysis reflects tumor evolution and the genomic alterations present in primary and/or metastatic tumors. Notably, ctDNA analysis might allow the stratification of patients, the monitoring of the therapeutic response, and the establishment of an opportunity for early intervention independent of detection by imaging modalities or clinical symptoms. As oncology moves towards precision medicine, the information in ctDNA provides a means for the individual management of the patient based on their tumor's genetic profile. This review presents current evidence on the potential role for ctDNA in helping to guide individualized clinical treatment decisions for patients with melanoma, castration-resistant prostate cancer, breast cancer, metastatic colorectal cancer, and non-small cell lung cancer.

引用

页码：517 / 528

页数：12

共 92 条

[81] Noninvasive genotyping and monitoring of anaplastic lymphoma kinase (ALK) rearranged non-small cell lung cancer by capture-based next-generation sequencing
Wang, Ye
Tian, Pan-Wen
Wang, Wei-Ya
Wang, Ke
Zhang, Zhou
Chen, Bo-Jiang
He, Yan-Qi
Li, Lei
Liu, Hao
Chuai, Shannon
Li, Wei-Min
[J]. ONCOTARGET, 2016, 7 (40) : 65208 - 65217
[82] Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel
Wang, Zhijie
Duan, Jianchun
Cai, Shangli
Han, Miao
Dong, Hua
Zhao, Jun
Zhu, Bo
Wang, Shuhang
Zhuo, Minglei
Sun, Jianguo
Wang, Qiming
Bai, Hua
Han, Jiefei
Tian, Yanhua
Lu, Jing
Xu, Tongfu
Zhao, Xiaochen
Wang, Guoqiang
Cao, Xinkai
Li, Fugen
Wang, Dalei
Chen, Yuejun
Bai, Yuezong
Zhao, Jing
Zhao, Zhengyi
Zhang, Yuzi
Xiong, Lei
He, Jie
Gao, Shugeng
Wang, Jie
[J]. JAMA ONCOLOGY, 2019, 5 (05) : 696 - 702
[83] Analysis of KRAS, NRAS, BRAF, and PIK3CA mutations could predict metastases in colorectal cancer: A preliminary study
Wojas-Krawczyk, Kamila
Kalinka-Warzocha, Ewa
Reszka, Katarzyna
Nicos, Marcin
Szumilo, Justyna
Mandziuk, Slawomir
Szczepaniak, Katarzyna
Kupnicka, Dorota
Lewandowski, Remigiusz
Milanowski, Janusz
Krawczyk, Pawel
[J]. ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, 2019, 28 (01): : 67 - 73
[84] First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study
Wu, Y. -L.
Zhou, C.
Liam, C. -K.
Wu, G.
Liu, X.
Zhong, Z.
Lu, S.
Cheng, Y.
Han, B.
Chen, L.
Huang, C.
Qin, S.
Zhu, Y.
Pan, H.
Liang, H.
Li, E.
Jiang, G.
How, S. H.
Fernando, M. C. L.
Zhang, Y.
Xia, F.
Zuo, Y.
[J]. ANNALS OF ONCOLOGY, 2015, 26 (09) : 1883 - 1889
[85] Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer
Wyatt, Alexander W.
Annala, Matti
Aggarwal, Rahul
Beja, Kevin
Feng, Felix
Youngren, Jack
Foye, Adam
Lloyd, Paul
Nykter, Matti
Beer, Tomasz M.
Alumkal, Joshi J.
Thomas, George V.
Reiter, Robert E.
Rettig, Matthew B.
Evans, Christopher P.
Gao, Allen C.
Chi, Kim N.
Small, Eric J.
Gleave, Martin E.
[J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2018, 110 (01):
[86] Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer
Wyatt, Alexander W.
Azad, Arun A.
Volik, Stanislav V.
Annala, Matti
Beja, Kevin
McConeghy, Brian
Haegert, Anne
Warner, Evan W.
Mo, Fan
Brahmbhatt, Sonal
Shukin, Robert
Le Bihan, Stephane
Gleave, Martin E.
Nykter, Matti
Collins, Colin C.
Chi, Kim N.
[J]. JAMA ONCOLOGY, 2016, 2 (12) : 1598 - 1606
[87] Circulating Tumor DNA as an Early Indicator of Response to T-cell Transfer Immunotherapy in Metastatic Melanoma
Xi, Liqiang
Pham, Trinh Hoc-Tran
Payabyab, Eden C.
Sherry, Richard M.
Rosenberg, Steven A.
Raffeld, Mark
[J]. CLINICAL CANCER RESEARCH, 2016, 22 (22) : 5480 - 5486
[88] Utility of KRAS mutation detection using circulating cell-free DNA from patients with colorectal cancer
Yamada, Takeshi
Iwai, Takuma
Takahashi, Goro
Kan, Hayato
Koizumi, Michihiro
Matsuda, Akihisa
Shinji, Seiichi
Yamagishi, Aya
Yokoyama, Yasuyuki
Tatsuguchi, Atsushi
Kawagoe, Tatsuro
Kitano, Shiro
Nakayama, Masato
Matsumoto, Satoshi
Uchida, Eiji
[J]. CANCER SCIENCE, 2016, 107 (07) : 936 - 943
[89] Precision medicine becomes reality-tumor type-agnostic therapy
Yan, Li
Zhang, Wei
[J]. CANCER COMMUNICATIONS, 2018, 38
[90] Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
Yu, Helena A.
Arcila, Maria E.
Rekhtman, Natasha
Sima, Camelia S.
Zakowski, Maureen F.
Pao, William
Kris, Mark G.
Miller, Vincent A.
Ladanyi, Marc
Riely, Gregory J.
[J]. CLINICAL CANCER RESEARCH, 2013, 19 (08) : 2240 - 2247

← 1 2 3 4 5 6 7 8 9 10 →